A Single-Patient Study Using AGS 006 as an Immunotherapeutic in a Subject With Newly Diagnosed Resectable Pancreatic Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Incidence of treatment-emergent adverse events graded according to the Common Terminology Criteria for Adverse Events
研究概览
简要总结
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
详细描述
Single-patient, open-label clinical study:
- Events during Pre-Treatment Period:
- Resection of pancreatic cancer,
- RNA acquisition from tumor specimen,
- RNA amplification,
- Infectious disease testing,
- Autoimmune disease testing,
- Two blood draws for immune response monitoring,
- Production leukapheresis, and
- Dendritic cell electroporation with RNA and immunotherapeutic production;
- Events during Induction Period:
- Administer investigative treatment every 2 weeks for a total of five doses, followed by dosing every 4 weeks for a total of four doses,
- Two Induction Period blood draws (Week 6 and Week 12) for immune response monitoring, and
- One leukapheresis (Week 14) for immune response monitoring;
- Events during Booster Period:
- Dose every 3 months until progression or 2 years after first AGS treatment,
- Potentially, one leukapheresis for immune response monitoring 12 months from the first dose, and
- One blood draw 2 weeks following dosing at Week 36 (1st booster dose) (approximately Week 38); and,
- Events during study Close-Out:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •A male subject 18 years of age or older with newly diagnosed resectable pancreatic cancer who, in the opinion of the investigator, is suitable for participation in the study will be eligible for inclusion if all of the following criteria apply:
- •Able to abstain from taking prohibited prescription or prohibited non-prescription drugs.
- •Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.
- •Voluntary informed consent given to participate in the study.
排除标准
- •Any serious medical condition such as cardiopulmonary disease, circulatory compromise, hepatic or renal dysfunction, or other illness considered by the investigator to constitute an unwarranted high risk for investigational treatment.
- •Active autoimmune disease including, but not limited to:
- •Active, acute, or chronic clinically significant infections including human immunodeficiency virus (HIV) and viral hepatitis.
- •Known hypersensitivity to dimethyl sulfoxide (DMSO).
- •Body weight less than 30 kg.
结局指标
主要结局
Incidence of treatment-emergent adverse events graded according to the Common Terminology Criteria for Adverse Events
Treatment-emergent changes in vital signs (blood pressure, heart rate, respiratory rate, and body temperature) from baseline values obtained prior to each investigative treatment
Treatment-emergent adenopathy, tenderness, or inflammation (inguinal and axillary) assessed before and after each dose
Treatment-emergent changes in autoimmunity evaluations as measured by clinical signs and symptoms and laboratory assessments at periodic intervals during the Treatment Period.
Treatment-emergent changes in localized injection site reactions following each dose
次要结局
- Assessment of progression-free survival (PFS) estimated from the date of subject registration - Standard Response Evaluation Criteria in Solid Tumors (RECIST) definitions of progressive disease (PD) will contribute to estimating the interval for PFS.
- T cell response to RNA-electroporated DCs will be assessed by flow cytometry using blood cells collected according to protocol time and events
- Positive immune response
- Feasibility